Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Is Hormone Replacement Therapy Safe in Women With a BRCA Mutation?: A Systematic Review of the Contemporary Literature.

American journal of clinical oncology - 1 Mar 2018

Birrer Nicole, Chinchilla Carolina, Del Carmen Marcela, Dizon Don S

Abstract excerpt

OBJECTIVES: Women with a BRCA1 or BRCA2 mutation are recommended to undergo prophylactic (or risk reducing) bilateral salpingo-oophorectomy (BSO) before age 40, resulting in surgical menopause. Given the concerns of estrogen deprivation on overall health, hormone therapy (HT) is often discussed, yet safety concerns persist. MATERIALS AND METHODS: We performed a systematic literature review of the safety of HT in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Predisposition to Disease

Share to Hormone Replacement Therapy

Share to Menopause, Premature

Share to Mutation

Share to Ovarian Neoplasms

Share to Salpingo-oophorectomy

Source

Identifiers

PMID: 26840041
DOI: 10.1097/COC.0000000000000269

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Is Hormone Replacement Therapy Safe in Women With a BRCA Mutation?: A Systematic Review of the Contemporary Literature.PMID 26840041Read ↗

Hormone replacement therapy in BRCA mutation carriers: how shall we do no harm?Semantic proximity Read ↗

Hormone therapy after risk-reducing surgery in patients with BRCA1/BRCA2 mutation: evaluation of potential benefits and safety.Semantic proximity Read ↗

Hormonal management after risk-reducing surgery in BRCA-mutated triple-negative breast cancer survivors.Semantic proximity Read ↗

Hormone replacement therapy in BRCA mutation carriers and risk of ovarian, endometrial, and breast cancer: a systematic review.Semantic proximity Read ↗

The Role of Hormonal Replacement Therapy in BRCA Mutated Patients: Lights and Shadows.Semantic proximity Read ↗

BRCA carriers, prophylactic salpingo-oophorectomy and menopause: clinical management considerations and recommendations.Semantic proximity Read ↗

Factors associated with use of hormone therapy after preventive oophorectomy in BRCA mutation carriers.Semantic proximity Read ↗

Use of systemic hormone therapy in BRCA mutation carriers.Semantic proximity Read ↗

Menopausal hormone therapy and the risk of breast cancer in women with a pathogenic variant in BRCA1 or BRCA2.Semantic proximity Read ↗

Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers.Semantic proximity Read ↗

Breast cancer risk and hormone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy.Semantic proximity Read ↗

BRCA carriers after risk-reducing bilateral salpingo-oophorectomy: menopausal hormone therapy knowledge gaps, and the impact of physicians' recommendations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.